News and Updates

* August 26, 2005 .::. San Diego, California

An article appeared in the Wallstreet Journal entitled "A Low-Tech Way to Find Colon Cancer: Home Screening Tests Get More Reliable" by Tara Parker-Pope on the 23rd of August. It exlpained the importance of FOBTs and also gave some background information on how these products have evolved. FOBTs will help people to detect Colon Rectal Cancer early on, which is a cureable disease. More information about colon cancer can be found at American Cancer Society:Can Colorectal Polyps and Cancer be Found Early?

The artical from the Wallstreet Journal can be found through the following link:

A Low-Tech Way to Find Colon Cancer: Home Screening Tests Get More Reliable

* June 24, 2005 .::. San Diego, California

Epitope Diagnostics will launch its innovative fecal sample-based rapid immunoassy test platform during the AACC meeting. This novel fecal sample test system is so user-friendly that it protects both the test preformer and the environment and does not leak bad smells into the testing area. This test system is a closed, or nearly closed, fecal sampling and immunoassy system that allows the test procedure to be conducted without exposing stool samples into the testing environment.

Fecal samples are the third most important labratory test specimen, along with blood and urine. The most common fecal specimen based tests inlcude the Fecal Occult Blood Test (FOBT), Rotavirus Antigen Test, Adenovirus Antigen Test, Giardia Lamblia Anitigen Test, Cryptosporidian Pavum Test, Amoeba Test and H. Pylori Test, etc.

* June 24, 2005 .::. San Diego, California

Epitope Diagnostics will exhibit at Clin Lab Expo during AACC's annual meeting at the Orange County Convention Center in Orlando, Florida. This will take place during July 25-28, 2005 and our booth number is 2636. We are currently looking for distributors from various countries.

* June 2, 2005 .::. San Diego, California

Epitope Diagnostics is pleased to announce that its ELISA test kits are CE marked. These kits include the fetuin-A ELISA kit, chromogranin-A ELISA kit, and pepsinogen I and II ELISA kits. We are a primary immunoassay developer and manufacturer.

* March 8, 2005 .::. San Diego, California

Epitope Diagnostics is very happy to announce its manufacture facility is lisenced and approved by the state FDA for medical device production. This major achievement reflects that the company is focused and dedicated to comply with the quality management system, and delivers its products with excellent performace characteristics and great customer satifaction.

* November 2, 2004 .::. San Diego California

Epitope Diagnostics has developed a new ELISA kit for quantitative measurement of human chromogranin-A in serum. This kit gives the true value of chromogranin-A in nanograms per milliliter with a normal cutoff of 100 ng/mL. It is reported that chromogranin-A is a useful marker in the aid of diagnosis and monitering of patients with pheochormocytoma, neuro-endocrine tumors, or small cell lung cancer. This kit is commercially available and its catalog number is KT812. If you have any question please contact customer service at cs@epitopediagnostics.com.

July 27 - 29, 2004 AACC Annual Meeting (Los Angeles)

Epitope Diagnostics exhibited at AACC 2004 Annual Meeting in Los Angeles. Thanks to all of you who visited our booth and supported our business. We appreciate that you are dedicated to bringing high quality and advanced new diagnostic technology to your patients.

* December 12, 2003 .::. San Diego, California

Epitope Diagnostics has developed a human fetuin-A (AHSG) ELISA kit. This is the first commercial kit of its kind in the market. Fetuin-A is a major calcification regulator in circulation. Recent studies have shown that fetuin-A defficency is present in patients with chronic kidney disease, and that is associated with high incidents of cardiovascular calcification and poor survival rates.